David A. Siegel Ikena Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 144,100 shares of IKNA stock, worth $198,857. This represents 0.0% of its overall portfolio holdings.
Number of Shares
144,100
Previous 151,400
4.82%
Holding current value
$198,857
Previous $193,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding IKNA
# of Institutions
44Shares Held
33.6MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$6.93 Million1.48% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$5.65 Million2.97% of portfolio
-
Bml Capital Management, LLC Zionsville, IN4.03MShares$5.56 Million4.09% of portfolio
-
Bvf Inc San Francisco, CA4.01MShares$5.53 Million0.21% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$4.88 Million0.17% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $50M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...